Recommended Dosage: The recommended dosage of ONGLYZA is 5 mg once daily taken regardless of meals. ONGLYZA tablets must not be split or cut.
Dosage in Patients with Renal Impairment: No dosage adjustment for ONGLYZA is recommended for patients with eGFR ≥45 mL/min/1.73 m2.
ONGLYZA 5 mg once daily is not recommended for patients with eGFR <45 mL/min/1.73 m2 (which includes a subset of moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis) [see Pharmacology and Pharmacodynamics: Clinical Studies under Actions].
Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.
Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors: ONGLYZA 5 mg once daily is not recommended to be coadministered with strong cytochrome CYP3A4/5 inhibitors [see Interactions and Pharmacology under Actions].
Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin: When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia [see Precautions].